Malaria Vaccines

Malaria Vaccines Comprehensive Study by Type (Erythrocytic Vaccines, Combination Vaccines, Vectored Vaccines, Pre-Erythrocytic Vaccines, Others), Application (Hospitals, Specialty Clinics, Research Institute, Others), Agent (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, Others), Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others) Players and Region - Global Market Outlook to 2030

Malaria Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Malaria Vaccines
Malaria vaccines are biological preparations that aim to stimulate the body's immune system to protect against infection from the malaria parasite. Malaria is a serious and sometimes fatal illness caused by a parasite that lives in the blood of humans. It was developed specifically to target the deadliest malaria parasite, Plasmodium falciparum. The vaccine targets a specific protein on the surface of the malaria parasite called the circumsporozoite protein (CSP). The vaccine prompts the immune system to produce antibodies against the CSP protein. The field of malaria vaccines is experiencing exciting growth with large-scale implementation underway. Continued research holds promise for even better vaccines in the future.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Key players are adopting numerous strategies to gain market attention and to increase their market share, this strategy can be listed as increasing product portfolio, making partnerships to adopt certain technologies, and acquiring small players to finish the competition in the future. As well as investing money in the R&D sector to make technical upgrades to the product. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Malaria Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AdvaCare Pharma (United States), Ipca Laboratories Ltd. (India), GeoVax (United States), GSK plc. (United Kingdom), Sumaya Biotech (Germany), VLP Therapeutics (United States), OSIVAX (France), Ajanta Pharma Ltd. (India), Mylan N.V. (United States) and Zydus Cadila (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Cipla Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), Hikma Pharmaceuticals PLC (United Kingdom), Amneal Pharmaceuticals LLC. (United States) and Bliss GVS Pharma Ltd. (India).

Segmentation Overview
AMA Research has segmented the market of Global Malaria Vaccines market by Type (Erythrocytic Vaccines, Combination Vaccines, Vectored Vaccines, Pre-Erythrocytic Vaccines and Others), Application (Hospitals, Specialty Clinics, Research Institute and Others) and Region.



On the basis of geography, the market of Malaria Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Agent, the sub-segment i.e. Plasmodium Falciparum will boost the Malaria Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Intramuscular will boost the Malaria Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Investment for Healthcare Infrastructure

Market Growth Drivers:
Rising Burden of Malaria and Increased Awareness of Malaria

Challenges:
The Complexity of the Malaria Parasite

Restraints:
Developing and Distributing Vaccines can be Expensive

Opportunities:
The Development of More Effective Delivery Systems and Growing Government Support

Market Leaders and their expansionary development strategies
In October 2023, UNICEF announced an agreement to secure supply of the world’s second malaria vaccine, R21/Matrix-M. The deal is a major milestone towards meeting the high demand for doses of new vaccines against malaria – a disease which still kills one child under five every minute. The long-term agreement signed with Serum Life Sciences is conditional on vaccine pre-qualification from the World Health Organization.
In October 2021, GlaxoSmithKline (GSK) plc welcomes and applauds the World Health Organization's (WHO) proposal to launch and expand the use of GSK's RTS, S malaria vaccine in children with moderate to high transmission, as defined by WHO. RTS, S is the first and only malaria vaccine to be shown to reduce malaria in children in key long-term clinical trials dramatically.


Key Target Audience
Manufacturer, Government Bodies, Suppliers & Distributors, Regulatory Authorities, Research Center and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Erythrocytic Vaccines
  • Combination Vaccines
  • Vectored Vaccines
  • Pre-Erythrocytic Vaccines
  • Others
By Application
  • Hospitals
  • Specialty Clinics
  • Research Institute
  • Others
By Agent
  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Plasmodium Malariae
  • Others

By Route of Administration
  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Burden of Malaria
      • 3.2.2. Increased Awareness of Malaria
    • 3.3. Market Challenges
      • 3.3.1. The Complexity of the Malaria Parasite
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment for Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Malaria Vaccines, by Type, Application, Agent, Route of Administration and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Malaria Vaccines (Value)
      • 5.2.1. Global Malaria Vaccines by: Type (Value)
        • 5.2.1.1. Erythrocytic Vaccines
        • 5.2.1.2. Combination Vaccines
        • 5.2.1.3. Vectored Vaccines
        • 5.2.1.4. Pre-Erythrocytic Vaccines
        • 5.2.1.5. Others
      • 5.2.2. Global Malaria Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
        • 5.2.2.3. Research Institute
        • 5.2.2.4. Others
      • 5.2.3. Global Malaria Vaccines by: Agent (Value)
        • 5.2.3.1. Plasmodium Falciparum
        • 5.2.3.2. Plasmodium Vivax
        • 5.2.3.3. Plasmodium Malariae
        • 5.2.3.4. Others
      • 5.2.4. Global Malaria Vaccines by: Route of Administration (Value)
        • 5.2.4.1. Intramuscular
        • 5.2.4.2. Subcutaneous
        • 5.2.4.3. Intradermal
        • 5.2.4.4. Others
      • 5.2.5. Global Malaria Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Malaria Vaccines (Volume)
      • 5.3.1. Global Malaria Vaccines by: Type (Volume)
        • 5.3.1.1. Erythrocytic Vaccines
        • 5.3.1.2. Combination Vaccines
        • 5.3.1.3. Vectored Vaccines
        • 5.3.1.4. Pre-Erythrocytic Vaccines
        • 5.3.1.5. Others
      • 5.3.2. Global Malaria Vaccines by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Specialty Clinics
        • 5.3.2.3. Research Institute
        • 5.3.2.4. Others
      • 5.3.3. Global Malaria Vaccines by: Agent (Volume)
        • 5.3.3.1. Plasmodium Falciparum
        • 5.3.3.2. Plasmodium Vivax
        • 5.3.3.3. Plasmodium Malariae
        • 5.3.3.4. Others
      • 5.3.4. Global Malaria Vaccines by: Route of Administration (Volume)
        • 5.3.4.1. Intramuscular
        • 5.3.4.2. Subcutaneous
        • 5.3.4.3. Intradermal
        • 5.3.4.4. Others
      • 5.3.5. Global Malaria Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Malaria Vaccines (Price)
      • 5.4.1. Global Malaria Vaccines by: Type (Price)
  • 6. Malaria Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AdvaCare Pharma (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ipca Laboratories Ltd. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GeoVax (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GSK plc. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sumaya Biotech (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. VLP Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. OSIVAX (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ajanta Pharma Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mylan N.V. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zydus Cadila (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Malaria Vaccines Sale, by Type, Application, Agent, Route of Administration and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Malaria Vaccines (Value)
      • 7.2.1. Global Malaria Vaccines by: Type (Value)
        • 7.2.1.1. Erythrocytic Vaccines
        • 7.2.1.2. Combination Vaccines
        • 7.2.1.3. Vectored Vaccines
        • 7.2.1.4. Pre-Erythrocytic Vaccines
        • 7.2.1.5. Others
      • 7.2.2. Global Malaria Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
        • 7.2.2.3. Research Institute
        • 7.2.2.4. Others
      • 7.2.3. Global Malaria Vaccines by: Agent (Value)
        • 7.2.3.1. Plasmodium Falciparum
        • 7.2.3.2. Plasmodium Vivax
        • 7.2.3.3. Plasmodium Malariae
        • 7.2.3.4. Others
      • 7.2.4. Global Malaria Vaccines by: Route of Administration (Value)
        • 7.2.4.1. Intramuscular
        • 7.2.4.2. Subcutaneous
        • 7.2.4.3. Intradermal
        • 7.2.4.4. Others
      • 7.2.5. Global Malaria Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Malaria Vaccines (Volume)
      • 7.3.1. Global Malaria Vaccines by: Type (Volume)
        • 7.3.1.1. Erythrocytic Vaccines
        • 7.3.1.2. Combination Vaccines
        • 7.3.1.3. Vectored Vaccines
        • 7.3.1.4. Pre-Erythrocytic Vaccines
        • 7.3.1.5. Others
      • 7.3.2. Global Malaria Vaccines by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Specialty Clinics
        • 7.3.2.3. Research Institute
        • 7.3.2.4. Others
      • 7.3.3. Global Malaria Vaccines by: Agent (Volume)
        • 7.3.3.1. Plasmodium Falciparum
        • 7.3.3.2. Plasmodium Vivax
        • 7.3.3.3. Plasmodium Malariae
        • 7.3.3.4. Others
      • 7.3.4. Global Malaria Vaccines by: Route of Administration (Volume)
        • 7.3.4.1. Intramuscular
        • 7.3.4.2. Subcutaneous
        • 7.3.4.3. Intradermal
        • 7.3.4.4. Others
      • 7.3.5. Global Malaria Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Malaria Vaccines (Price)
      • 7.4.1. Global Malaria Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Malaria Vaccines: by Type(USD Million)
  • Table 2. Malaria Vaccines Erythrocytic Vaccines , by Region USD Million (2018-2023)
  • Table 3. Malaria Vaccines Combination Vaccines , by Region USD Million (2018-2023)
  • Table 4. Malaria Vaccines Vectored Vaccines , by Region USD Million (2018-2023)
  • Table 5. Malaria Vaccines Pre-Erythrocytic Vaccines , by Region USD Million (2018-2023)
  • Table 6. Malaria Vaccines Others , by Region USD Million (2018-2023)
  • Table 7. Malaria Vaccines: by Application(USD Million)
  • Table 8. Malaria Vaccines Hospitals , by Region USD Million (2018-2023)
  • Table 9. Malaria Vaccines Specialty Clinics , by Region USD Million (2018-2023)
  • Table 10. Malaria Vaccines Research Institute , by Region USD Million (2018-2023)
  • Table 11. Malaria Vaccines Others , by Region USD Million (2018-2023)
  • Table 12. Malaria Vaccines: by Agent(USD Million)
  • Table 13. Malaria Vaccines Plasmodium Falciparum , by Region USD Million (2018-2023)
  • Table 14. Malaria Vaccines Plasmodium Vivax , by Region USD Million (2018-2023)
  • Table 15. Malaria Vaccines Plasmodium Malariae , by Region USD Million (2018-2023)
  • Table 16. Malaria Vaccines Others , by Region USD Million (2018-2023)
  • Table 17. Malaria Vaccines: by Route of Administration(USD Million)
  • Table 18. Malaria Vaccines Intramuscular , by Region USD Million (2018-2023)
  • Table 19. Malaria Vaccines Subcutaneous , by Region USD Million (2018-2023)
  • Table 20. Malaria Vaccines Intradermal , by Region USD Million (2018-2023)
  • Table 21. Malaria Vaccines Others , by Region USD Million (2018-2023)
  • Table 22. South America Malaria Vaccines, by Country USD Million (2018-2023)
  • Table 23. South America Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 24. South America Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 25. South America Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 26. South America Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 27. Brazil Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 28. Brazil Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 29. Brazil Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 30. Brazil Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 31. Argentina Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 32. Argentina Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 33. Argentina Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 34. Argentina Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 35. Rest of South America Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 38. Rest of South America Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 39. Asia Pacific Malaria Vaccines, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 43. Asia Pacific Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 44. China Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 45. China Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 46. China Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 47. China Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 48. Japan Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 49. Japan Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 50. Japan Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 51. Japan Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 52. India Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 53. India Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 54. India Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 55. India Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 56. South Korea Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 57. South Korea Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 58. South Korea Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 59. South Korea Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 60. Taiwan Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 61. Taiwan Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 62. Taiwan Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 63. Taiwan Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 64. Australia Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 65. Australia Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 66. Australia Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 67. Australia Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 72. Europe Malaria Vaccines, by Country USD Million (2018-2023)
  • Table 73. Europe Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 74. Europe Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 75. Europe Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 76. Europe Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 77. Germany Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 78. Germany Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 79. Germany Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 80. Germany Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 81. France Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 82. France Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 83. France Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 84. France Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 85. Italy Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 86. Italy Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 87. Italy Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 88. Italy Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 89. United Kingdom Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 90. United Kingdom Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 91. United Kingdom Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 92. United Kingdom Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 93. Netherlands Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 94. Netherlands Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 95. Netherlands Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 96. Netherlands Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 97. Rest of Europe Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 98. Rest of Europe Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 99. Rest of Europe Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 100. Rest of Europe Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 101. MEA Malaria Vaccines, by Country USD Million (2018-2023)
  • Table 102. MEA Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 103. MEA Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 104. MEA Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 105. MEA Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 106. Middle East Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 107. Middle East Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 108. Middle East Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 109. Middle East Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 110. Africa Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 111. Africa Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 112. Africa Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 113. Africa Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 114. North America Malaria Vaccines, by Country USD Million (2018-2023)
  • Table 115. North America Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 116. North America Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 117. North America Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 118. North America Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 119. United States Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 120. United States Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 121. United States Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 122. United States Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 123. Canada Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 124. Canada Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 125. Canada Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 126. Canada Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 127. Mexico Malaria Vaccines, by Type USD Million (2018-2023)
  • Table 128. Mexico Malaria Vaccines, by Application USD Million (2018-2023)
  • Table 129. Mexico Malaria Vaccines, by Agent USD Million (2018-2023)
  • Table 130. Mexico Malaria Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 131. Malaria Vaccines Sales: by Type(Units)
  • Table 132. Malaria Vaccines Sales Erythrocytic Vaccines , by Region Units (2018-2023)
  • Table 133. Malaria Vaccines Sales Combination Vaccines , by Region Units (2018-2023)
  • Table 134. Malaria Vaccines Sales Vectored Vaccines , by Region Units (2018-2023)
  • Table 135. Malaria Vaccines Sales Pre-Erythrocytic Vaccines , by Region Units (2018-2023)
  • Table 136. Malaria Vaccines Sales Others , by Region Units (2018-2023)
  • Table 137. Malaria Vaccines Sales: by Application(Units)
  • Table 138. Malaria Vaccines Sales Hospitals , by Region Units (2018-2023)
  • Table 139. Malaria Vaccines Sales Specialty Clinics , by Region Units (2018-2023)
  • Table 140. Malaria Vaccines Sales Research Institute , by Region Units (2018-2023)
  • Table 141. Malaria Vaccines Sales Others , by Region Units (2018-2023)
  • Table 142. Malaria Vaccines Sales: by Agent(Units)
  • Table 143. Malaria Vaccines Sales Plasmodium Falciparum , by Region Units (2018-2023)
  • Table 144. Malaria Vaccines Sales Plasmodium Vivax , by Region Units (2018-2023)
  • Table 145. Malaria Vaccines Sales Plasmodium Malariae , by Region Units (2018-2023)
  • Table 146. Malaria Vaccines Sales Others , by Region Units (2018-2023)
  • Table 147. Malaria Vaccines Sales: by Route of Administration(Units)
  • Table 148. Malaria Vaccines Sales Intramuscular , by Region Units (2018-2023)
  • Table 149. Malaria Vaccines Sales Subcutaneous , by Region Units (2018-2023)
  • Table 150. Malaria Vaccines Sales Intradermal , by Region Units (2018-2023)
  • Table 151. Malaria Vaccines Sales Others , by Region Units (2018-2023)
  • Table 152. South America Malaria Vaccines Sales, by Country Units (2018-2023)
  • Table 153. South America Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 154. South America Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 155. South America Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 156. South America Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 157. Brazil Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 158. Brazil Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 159. Brazil Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 160. Brazil Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 161. Argentina Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 162. Argentina Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 163. Argentina Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 164. Argentina Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 165. Rest of South America Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 166. Rest of South America Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 167. Rest of South America Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 168. Rest of South America Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 169. Asia Pacific Malaria Vaccines Sales, by Country Units (2018-2023)
  • Table 170. Asia Pacific Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 171. Asia Pacific Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 172. Asia Pacific Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 173. Asia Pacific Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 174. China Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 175. China Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 176. China Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 177. China Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 178. Japan Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 179. Japan Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 180. Japan Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 181. Japan Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 182. India Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 183. India Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 184. India Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 185. India Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 186. South Korea Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 187. South Korea Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 188. South Korea Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 189. South Korea Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 190. Taiwan Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 191. Taiwan Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 192. Taiwan Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 193. Taiwan Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 194. Australia Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 195. Australia Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 196. Australia Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 197. Australia Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 198. Rest of Asia-Pacific Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 199. Rest of Asia-Pacific Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 200. Rest of Asia-Pacific Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 201. Rest of Asia-Pacific Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 202. Europe Malaria Vaccines Sales, by Country Units (2018-2023)
  • Table 203. Europe Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 204. Europe Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 205. Europe Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 206. Europe Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 207. Germany Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 208. Germany Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 209. Germany Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 210. Germany Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 211. France Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 212. France Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 213. France Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 214. France Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 215. Italy Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 216. Italy Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 217. Italy Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 218. Italy Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 219. United Kingdom Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 220. United Kingdom Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 221. United Kingdom Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 222. United Kingdom Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 223. Netherlands Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 224. Netherlands Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 225. Netherlands Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 226. Netherlands Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 227. Rest of Europe Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 228. Rest of Europe Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 229. Rest of Europe Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 230. Rest of Europe Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 231. MEA Malaria Vaccines Sales, by Country Units (2018-2023)
  • Table 232. MEA Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 233. MEA Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 234. MEA Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 235. MEA Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 236. Middle East Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 237. Middle East Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 238. Middle East Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 239. Middle East Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 240. Africa Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 241. Africa Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 242. Africa Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 243. Africa Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 244. North America Malaria Vaccines Sales, by Country Units (2018-2023)
  • Table 245. North America Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 246. North America Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 247. North America Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 248. North America Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 249. United States Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 250. United States Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 251. United States Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 252. United States Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 253. Canada Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 254. Canada Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 255. Canada Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 256. Canada Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 257. Mexico Malaria Vaccines Sales, by Type Units (2018-2023)
  • Table 258. Mexico Malaria Vaccines Sales, by Application Units (2018-2023)
  • Table 259. Mexico Malaria Vaccines Sales, by Agent Units (2018-2023)
  • Table 260. Mexico Malaria Vaccines Sales, by Route of Administration Units (2018-2023)
  • Table 261. Malaria Vaccines: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Malaria Vaccines: by Type(USD Million)
  • Table 273. Malaria Vaccines Erythrocytic Vaccines , by Region USD Million (2025-2030)
  • Table 274. Malaria Vaccines Combination Vaccines , by Region USD Million (2025-2030)
  • Table 275. Malaria Vaccines Vectored Vaccines , by Region USD Million (2025-2030)
  • Table 276. Malaria Vaccines Pre-Erythrocytic Vaccines , by Region USD Million (2025-2030)
  • Table 277. Malaria Vaccines Others , by Region USD Million (2025-2030)
  • Table 278. Malaria Vaccines: by Application(USD Million)
  • Table 279. Malaria Vaccines Hospitals , by Region USD Million (2025-2030)
  • Table 280. Malaria Vaccines Specialty Clinics , by Region USD Million (2025-2030)
  • Table 281. Malaria Vaccines Research Institute , by Region USD Million (2025-2030)
  • Table 282. Malaria Vaccines Others , by Region USD Million (2025-2030)
  • Table 283. Malaria Vaccines: by Agent(USD Million)
  • Table 284. Malaria Vaccines Plasmodium Falciparum , by Region USD Million (2025-2030)
  • Table 285. Malaria Vaccines Plasmodium Vivax , by Region USD Million (2025-2030)
  • Table 286. Malaria Vaccines Plasmodium Malariae , by Region USD Million (2025-2030)
  • Table 287. Malaria Vaccines Others , by Region USD Million (2025-2030)
  • Table 288. Malaria Vaccines: by Route of Administration(USD Million)
  • Table 289. Malaria Vaccines Intramuscular , by Region USD Million (2025-2030)
  • Table 290. Malaria Vaccines Subcutaneous , by Region USD Million (2025-2030)
  • Table 291. Malaria Vaccines Intradermal , by Region USD Million (2025-2030)
  • Table 292. Malaria Vaccines Others , by Region USD Million (2025-2030)
  • Table 293. South America Malaria Vaccines, by Country USD Million (2025-2030)
  • Table 294. South America Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 295. South America Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 296. South America Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 297. South America Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 298. Brazil Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 299. Brazil Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 300. Brazil Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 301. Brazil Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 302. Argentina Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 303. Argentina Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 304. Argentina Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 305. Argentina Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 306. Rest of South America Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 307. Rest of South America Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 308. Rest of South America Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 309. Rest of South America Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 310. Asia Pacific Malaria Vaccines, by Country USD Million (2025-2030)
  • Table 311. Asia Pacific Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 312. Asia Pacific Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 313. Asia Pacific Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 314. Asia Pacific Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 315. China Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 316. China Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 317. China Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 318. China Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 319. Japan Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 320. Japan Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 321. Japan Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 322. Japan Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 323. India Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 324. India Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 325. India Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 326. India Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 327. South Korea Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 328. South Korea Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 329. South Korea Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 330. South Korea Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 331. Taiwan Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 332. Taiwan Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 333. Taiwan Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 334. Taiwan Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 335. Australia Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 336. Australia Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 337. Australia Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 338. Australia Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 342. Rest of Asia-Pacific Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 343. Europe Malaria Vaccines, by Country USD Million (2025-2030)
  • Table 344. Europe Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 345. Europe Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 346. Europe Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 347. Europe Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 348. Germany Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 349. Germany Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 350. Germany Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 351. Germany Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 352. France Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 353. France Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 354. France Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 355. France Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 356. Italy Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 357. Italy Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 358. Italy Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 359. Italy Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 360. United Kingdom Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 361. United Kingdom Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 362. United Kingdom Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 363. United Kingdom Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 364. Netherlands Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 365. Netherlands Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 366. Netherlands Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 367. Netherlands Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 368. Rest of Europe Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 369. Rest of Europe Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 370. Rest of Europe Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 371. Rest of Europe Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 372. MEA Malaria Vaccines, by Country USD Million (2025-2030)
  • Table 373. MEA Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 374. MEA Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 375. MEA Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 376. MEA Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 377. Middle East Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 378. Middle East Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 379. Middle East Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 380. Middle East Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 381. Africa Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 382. Africa Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 383. Africa Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 384. Africa Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 385. North America Malaria Vaccines, by Country USD Million (2025-2030)
  • Table 386. North America Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 387. North America Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 388. North America Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 389. North America Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 390. United States Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 391. United States Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 392. United States Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 393. United States Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 394. Canada Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 395. Canada Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 396. Canada Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 397. Canada Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 398. Mexico Malaria Vaccines, by Type USD Million (2025-2030)
  • Table 399. Mexico Malaria Vaccines, by Application USD Million (2025-2030)
  • Table 400. Mexico Malaria Vaccines, by Agent USD Million (2025-2030)
  • Table 401. Mexico Malaria Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 402. Malaria Vaccines Sales: by Type(Units)
  • Table 403. Malaria Vaccines Sales Erythrocytic Vaccines , by Region Units (2025-2030)
  • Table 404. Malaria Vaccines Sales Combination Vaccines , by Region Units (2025-2030)
  • Table 405. Malaria Vaccines Sales Vectored Vaccines , by Region Units (2025-2030)
  • Table 406. Malaria Vaccines Sales Pre-Erythrocytic Vaccines , by Region Units (2025-2030)
  • Table 407. Malaria Vaccines Sales Others , by Region Units (2025-2030)
  • Table 408. Malaria Vaccines Sales: by Application(Units)
  • Table 409. Malaria Vaccines Sales Hospitals , by Region Units (2025-2030)
  • Table 410. Malaria Vaccines Sales Specialty Clinics , by Region Units (2025-2030)
  • Table 411. Malaria Vaccines Sales Research Institute , by Region Units (2025-2030)
  • Table 412. Malaria Vaccines Sales Others , by Region Units (2025-2030)
  • Table 413. Malaria Vaccines Sales: by Agent(Units)
  • Table 414. Malaria Vaccines Sales Plasmodium Falciparum , by Region Units (2025-2030)
  • Table 415. Malaria Vaccines Sales Plasmodium Vivax , by Region Units (2025-2030)
  • Table 416. Malaria Vaccines Sales Plasmodium Malariae , by Region Units (2025-2030)
  • Table 417. Malaria Vaccines Sales Others , by Region Units (2025-2030)
  • Table 418. Malaria Vaccines Sales: by Route of Administration(Units)
  • Table 419. Malaria Vaccines Sales Intramuscular , by Region Units (2025-2030)
  • Table 420. Malaria Vaccines Sales Subcutaneous , by Region Units (2025-2030)
  • Table 421. Malaria Vaccines Sales Intradermal , by Region Units (2025-2030)
  • Table 422. Malaria Vaccines Sales Others , by Region Units (2025-2030)
  • Table 423. South America Malaria Vaccines Sales, by Country Units (2025-2030)
  • Table 424. South America Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 425. South America Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 426. South America Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 427. South America Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 428. Brazil Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 429. Brazil Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 430. Brazil Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 431. Brazil Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 432. Argentina Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 433. Argentina Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 434. Argentina Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 435. Argentina Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 436. Rest of South America Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 437. Rest of South America Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 438. Rest of South America Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 439. Rest of South America Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 440. Asia Pacific Malaria Vaccines Sales, by Country Units (2025-2030)
  • Table 441. Asia Pacific Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 442. Asia Pacific Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 443. Asia Pacific Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 444. Asia Pacific Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 445. China Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 446. China Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 447. China Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 448. China Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 449. Japan Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 450. Japan Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 451. Japan Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 452. Japan Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 453. India Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 454. India Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 455. India Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 456. India Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 457. South Korea Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 458. South Korea Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 459. South Korea Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 460. South Korea Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 461. Taiwan Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 462. Taiwan Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 463. Taiwan Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 464. Taiwan Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 465. Australia Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 466. Australia Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 467. Australia Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 468. Australia Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 469. Rest of Asia-Pacific Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 470. Rest of Asia-Pacific Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 471. Rest of Asia-Pacific Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 472. Rest of Asia-Pacific Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 473. Europe Malaria Vaccines Sales, by Country Units (2025-2030)
  • Table 474. Europe Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 475. Europe Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 476. Europe Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 477. Europe Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 478. Germany Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 479. Germany Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 480. Germany Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 481. Germany Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 482. France Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 483. France Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 484. France Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 485. France Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 486. Italy Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 487. Italy Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 488. Italy Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 489. Italy Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 490. United Kingdom Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 491. United Kingdom Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 492. United Kingdom Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 493. United Kingdom Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 494. Netherlands Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 495. Netherlands Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 496. Netherlands Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 497. Netherlands Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 498. Rest of Europe Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 499. Rest of Europe Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 500. Rest of Europe Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 501. Rest of Europe Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 502. MEA Malaria Vaccines Sales, by Country Units (2025-2030)
  • Table 503. MEA Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 504. MEA Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 505. MEA Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 506. MEA Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 507. Middle East Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 508. Middle East Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 509. Middle East Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 510. Middle East Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 511. Africa Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 512. Africa Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 513. Africa Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 514. Africa Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 515. North America Malaria Vaccines Sales, by Country Units (2025-2030)
  • Table 516. North America Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 517. North America Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 518. North America Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 519. North America Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 520. United States Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 521. United States Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 522. United States Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 523. United States Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 524. Canada Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 525. Canada Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 526. Canada Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 527. Canada Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 528. Mexico Malaria Vaccines Sales, by Type Units (2025-2030)
  • Table 529. Mexico Malaria Vaccines Sales, by Application Units (2025-2030)
  • Table 530. Mexico Malaria Vaccines Sales, by Agent Units (2025-2030)
  • Table 531. Mexico Malaria Vaccines Sales, by Route of Administration Units (2025-2030)
  • Table 532. Malaria Vaccines: by Type(USD/Units)
  • Table 533. Research Programs/Design for This Report
  • Table 534. Key Data Information from Secondary Sources
  • Table 535. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Malaria Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Malaria Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Malaria Vaccines: by Agent USD Million (2018-2023)
  • Figure 7. Global Malaria Vaccines: by Route of Administration USD Million (2018-2023)
  • Figure 8. South America Malaria Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Malaria Vaccines Share (%), by Country
  • Figure 10. Europe Malaria Vaccines Share (%), by Country
  • Figure 11. MEA Malaria Vaccines Share (%), by Country
  • Figure 12. North America Malaria Vaccines Share (%), by Country
  • Figure 13. Global Malaria Vaccines: by Type Units (2018-2023)
  • Figure 14. Global Malaria Vaccines: by Application Units (2018-2023)
  • Figure 15. Global Malaria Vaccines: by Agent Units (2018-2023)
  • Figure 16. Global Malaria Vaccines: by Route of Administration Units (2018-2023)
  • Figure 17. South America Malaria Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Malaria Vaccines Share (%), by Country
  • Figure 19. Europe Malaria Vaccines Share (%), by Country
  • Figure 20. MEA Malaria Vaccines Share (%), by Country
  • Figure 21. North America Malaria Vaccines Share (%), by Country
  • Figure 22. Global Malaria Vaccines: by Type USD/Units (2018-2023)
  • Figure 23. Global Malaria Vaccines share by Players 2023 (%)
  • Figure 24. Global Malaria Vaccines share by Players (Top 3) 2023(%)
  • Figure 25. Global Malaria Vaccines share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AdvaCare Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 28. AdvaCare Pharma (United States) Revenue: by Geography 2023
  • Figure 29. Ipca Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Ipca Laboratories Ltd. (India) Revenue: by Geography 2023
  • Figure 31. GeoVax (United States) Revenue, Net Income and Gross profit
  • Figure 32. GeoVax (United States) Revenue: by Geography 2023
  • Figure 33. GSK plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GSK plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Sumaya Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Sumaya Biotech (Germany) Revenue: by Geography 2023
  • Figure 37. VLP Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 38. VLP Therapeutics (United States) Revenue: by Geography 2023
  • Figure 39. OSIVAX (France) Revenue, Net Income and Gross profit
  • Figure 40. OSIVAX (France) Revenue: by Geography 2023
  • Figure 41. Ajanta Pharma Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 42. Ajanta Pharma Ltd. (India) Revenue: by Geography 2023
  • Figure 43. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 45. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 46. Zydus Cadila (India) Revenue: by Geography 2023
  • Figure 47. Global Malaria Vaccines: by Type USD Million (2025-2030)
  • Figure 48. Global Malaria Vaccines: by Application USD Million (2025-2030)
  • Figure 49. Global Malaria Vaccines: by Agent USD Million (2025-2030)
  • Figure 50. Global Malaria Vaccines: by Route of Administration USD Million (2025-2030)
  • Figure 51. South America Malaria Vaccines Share (%), by Country
  • Figure 52. Asia Pacific Malaria Vaccines Share (%), by Country
  • Figure 53. Europe Malaria Vaccines Share (%), by Country
  • Figure 54. MEA Malaria Vaccines Share (%), by Country
  • Figure 55. North America Malaria Vaccines Share (%), by Country
  • Figure 56. Global Malaria Vaccines: by Type Units (2025-2030)
  • Figure 57. Global Malaria Vaccines: by Application Units (2025-2030)
  • Figure 58. Global Malaria Vaccines: by Agent Units (2025-2030)
  • Figure 59. Global Malaria Vaccines: by Route of Administration Units (2025-2030)
  • Figure 60. South America Malaria Vaccines Share (%), by Country
  • Figure 61. Asia Pacific Malaria Vaccines Share (%), by Country
  • Figure 62. Europe Malaria Vaccines Share (%), by Country
  • Figure 63. MEA Malaria Vaccines Share (%), by Country
  • Figure 64. North America Malaria Vaccines Share (%), by Country
  • Figure 65. Global Malaria Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • AdvaCare Pharma (United States)
  • Ipca Laboratories Ltd. (India)
  • GeoVax (United States)
  • GSK plc. (United Kingdom)
  • Sumaya Biotech (Germany)
  • VLP Therapeutics (United States)
  • OSIVAX (France)
  • Ajanta Pharma Ltd. (India)
  • Mylan N.V. (United States)
  • Zydus Cadila (India)
Additional players considered in the study are as follows:
Cipla Inc. (United States) , Sun Pharmaceutical Industries Ltd. (India) , Sanofi (France) , Hikma Pharmaceuticals PLC (United Kingdom) , Amneal Pharmaceuticals LLC. (United States) , Bliss GVS Pharma Ltd. (India)
Select User Access Type

Key Highlights of Report


Mar 2024 241 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Malaria Vaccines Quantitative research analysis
Malaria Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AdvaCare Pharma (United States), Ipca Laboratories Ltd. (India), GeoVax (United States), GSK plc. (United Kingdom), Sumaya Biotech (Germany), VLP Therapeutics (United States), OSIVAX (France), Ajanta Pharma Ltd. (India), Mylan N.V. (United States) and Zydus Cadila (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Investment for Healthcare Infrastructure" is seen as one of major influencing trends for Malaria Vaccines Market during projected period 2023-2030.
The Malaria Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Malaria Vaccines Report?

Have a Query? Click Here

Other Related Reports

eHealth Comprehensive Study by Type (Electronic Health Records (EHR), Vendor Neutral Archive (VNA) and Picture Archiving & Communications Systems(PACS), Laboratory Information Systems (LIS), Teleheal...
$ 3800
Equine Healthcare Comprehensive Study by Type (Supplement Product, Therapeutic Product, Diagnostic Product), Application (Race Equine, Sport Equine), Therapeutic (Equine Therapeutics Market, Equine ...
$ 3750
Consumer Healthcare Products Comprehensive Study by Type (Pain Relief Product, Oral Health Product, Respiratory Product, Nutrition/Gastro Intestinal Product, Skin Health Product), Application (Hospit...
$ 3750
Sleeping Aids Comprehensive Study by Type (Medication, Mattresses and Pillows, Sleep Laboratories, Sleep Apnea Devices, Others), Application (Insomnia, Restless Legs Syndrome, Sleep Apnea, Narcolepsy...
$ 3350
Western Blotting Comprehensive Study by Type (Consumables {Reagents, Kits and Other}, Instruments {Blotting Systems (Wet and Semi-Dry) and Imagers (Chemiluminescent, Fluorescent and Other)}), Applica...
$ 3650
Orthopedic Shoes Comprehensive Study by Type (Flatfoot Orthopedic Shoes, Cavus Orthopedic Shoes, Calcaneal Spur Orthopedic Shoes, Varus and Valgus Orthopedic Shoes, Other), Application (Children, Adu...
$ 3450